Author + information
- Kwang Kon Koh1
We have reported significantly differential effects of omega-3 fatty acids (n-3 FA) and fenofibrate and even high dose of n-3 FA. However, effects of n-3 FA combined with fenofibrate are not yet investigated, compared with fenofibrate.
This was a randomized, single-blind, placebo-controlled, parallel study. Age, sex, and body mass index were matched among groups. All patients were recommended to maintain a low fat diet. Fifty patients with hypertriglyceridemia in each group were given placebo, n-3 FA 2 g+fenofibrate 160 mg (combination), or fenofibrate 160 mg, respectively daily for 2 months.
When compared with placebo, both combination and fenofibrate significantly decreased apolipoprotein B and non-HDL cholesterol and improved flow-mediated dilation and reduced CRP and fibrinogen (all P < 0.05 by ANOVA), however, there were no significant differences between combination and fenofibrate. When compared with placebo, both combination and fenofibrate significantly reduced insulin and glucose (both P < 0.05 by ANOVA), and improved insulin sensitivity (P=0.005 by ANOVA). However, there were no significant differences between combination and fenofibrate.
When compared with fenofibrate, combination significantly decreased triglycerides and triglycerides/HDL cholesterol. Otherwise, combination and fenofibrate significantly improved insulin sensitivity by reducing insulin and glucose to a similar extent in patients with hypertriglyceridemia.